Eliminate Tuberculosis (TB)

The air-borne disease is curable, yet remains a significant global public health problem.

Tuberculosis (TB) has killed more people than any other infectious disease in history. The air-borne disease is curable, yet through relative political and financial neglect, it remains a significant global public health problem, thriving in disadvantaged communities with little visibility.

Each year, more than 1.5 million people die from TB and another nine million people, many children, struggle to overcome the debilitating effects of the disease. The majority of the global burden is in the Asia-Pacific region.

Tuberculosis global incidence and deaths

Burnet’s breadth of cross-disciplinary expertise brings together a highly diverse approach to tackling infectious diseases of global significance, including TB.

The key goals of the Eliminate TB program are:

  • Working towards the global targets to eliminate TB as a public health threat by 2030 through partnerships, community engagement, technical assistance to national programs, and accelerating the implementation of innovation and research.

  • Developing and evaluating new tools, technologies and strategies for prevention, diagnosis, treatment and care, through discovery, translational and operational research.

Contact Details

Associate Professor Suman Majumdar

Deputy Program Director, Health Security and Pandemic Preparedness; Co-head, Tuberculosis Elimination & Implementation Science; Principal Research Fellow




  • Building a Centre of Excellence for Research and Training for DR-TB in Daru, Papua New Guinea

  • Building capacity and improving tuberculosis diagnosis in Timor-Leste

  • Decision science using Optima

  • Demonstrating the impact of next generation Cepheid tools in TB

  • Diagnostic accuracy of Molbio Truenat for diagnosis of TB and rifampicin resistance

  • ESCAPE-TB: Enhanced screening and preventive therapy for TB in Daru, PNG

  • Evelyn Lavu Travel Scholarship

  • Improving Tuberculosis Services in Timor-Leste

  • Optima Tuberculosis (TB) Modelling

  • Predicting quality and potency of monoclonal and natural antibodies

  • PRIME-TB: Papua New Guinea & Republic of Indonesia for the Micro Elimination of TB

  • Rapid and accurate diagnosis of TB: New trial in PNG

  • RID-TB Patient Education and Counselling

  • RID-TB: Reducing the Impact of Drug-Resistant TB in Western Province, PNG

  • Tackling TB and HIV Together in Papua New Guinea

  • The EZARET Study: Exploring Zoonotic Association and Risks for Extrapulmonary Tuberculosis in PNG

  • The Social and Cultural Determinants of TB in Daru [SCuD-TB Daru – Study 1]

  • Zero TB initiative Yogyakarta

Latest News

    20 December, 2022

    2022 in Review: January to June

    As the third year of the pandemic got underway, Burnet continued its COVID-19 advocacy around a vaccines plus approach and advanced important work in malaria, tuberculosis and hepatitis C.

    13 September, 2022

    Reflecting on the importance of the 56th PNG Medical Symposium

    Locally led conferences allow for the sharing of new ideas as well as insights into local issues that aren’t always evident at more internationally focussed meetings, writes Dr Stefanie Vaccher.